Myrbetriq
Product Images NDC 55154-8713

Product Visual Gallery

This gallery contains 17 technical images submitted to the FDA as part of the official labeling for Myrbetriq (NDC 55154-8713). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cardinal Health 107, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

988efbea 7199 4a8b Ac71 005aba502572 00

This is a medication packaging label for Wyrbetra tablets, marketed by Astellas Pharma US, Inc. The tablets are made of Svalloy and should not be cut, crushed, or chewed. The label includes information on dosage, safety closures, and manufacturer NDC. The label also provides a contact number and website for patients to obtain information and instructions.*

FDA Label Image

988efbea 7199 4a8b Ac71 005aba502572 01

Myrbetriq is a medication that comes in the form of a tablet that must be swallowed whole, without cutting or crushing it. The recommended dosage is once-daily by mouth, and the complete prescribing information and warnings can be found in the product insert. The product must be stored at a temperature of 25°C with excursions permitted up to 30°C. It is important to note that safety closures must be used when handling the product unless otherwise directed by the physician. Myrbetriq is a registered trademark of Astellas Pharma Inc. and is distributed by Cardinal Health. For patient information, one can call 1-800-727-7003 or visit www.myrbetriq.com.*

FDA Label Image

Bottle Label (Image 01)

FDA Label Image

Bottle Label (Image 02)

FDA Label Image

Astellas Logo (Image 03)

FDA Label Image

Image 04

FDA Label Image

Image 05

FDA Label Image

Image 08

This appears to be a chart or table with various drugs and their recommended dosages based on their effect on the enzyme CYP3ARgp. The table lists the drug name, dosage, the fold change in PK, 80% confidence interval, and a recommendation for dose adjustment. The drugs listed are ketoconazole, fitampicin, solifenacin, tamsulosin, and metformin. However, the chart is not complete and lacks further context or explanation.*

FDA Label Image

Image 09

This is a table with information about the recommended dose adjustment for different drugs based on their interaction with CYP3A and CYP2D substrates. Some of the drugs require no dose adjustment, while others need caution or starting dose adjustment. The table also includes mean change relative to the substrate alone.*

FDA Label Image

Image 10

FDA Label Image

Image 11

FDA Label Image

Image 12

FDA Label Image

Image 13

FDA Label Image

Image 14

FDA Label Image

Image 15

FDA Label Image

Image 16

FDA Label Image

Image 17

The description is related to a table of values for "Adjusted Change From Baseline" at different time points during a medical study using a placebo and two different dosages of medication. The dosages were M25mg and M50mg. The study evaluated the participants for 12 weeks. The description of the study design ends abruptly, and there is not sufficient information to provide more insight.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.